Attivare Therapeutics develops the ATTImmune platform, a biomaterial scaffold that creates a localized microenvironment to recruit, activate, and reprogram immune cells at tumor sites. By loading the scaffold with customizable immunomodulators such as cytokines, CpG or mRNA, the platform delivers 3D spatiotemporal control of immune activation, enhancing the magnitude and durability of anti‑tumor responses for low‑immunogenic cancers and potentially infectious diseases.
Funding
$5.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many solid tumors and certain cancers such as acute myeloid leukemia exhibit low immunogenicity, making them resistant to conventional immunotherapies that rely on natural immune recognition. This resistance limits treatment efficacy and durability, leaving patients with few effective therapeutic options.
Solution
Attivare Therapeutics has created the ATTImmune platform, a biomaterial scaffold that establishes a localized microenvironment to concentrate and activate immune cells directly at the tumor site. The scaffold can be loaded with customizable immunomodulators—such as IL‑12, GM‑CSF, CpG, or mRNA—to reprogram resident immune cells and overcome tolerance to cancer antigens. By delivering these agents in a three‑dimensional, spatiotemporal controlled manner, the platform amplifies both the magnitude and durability of the anti‑tumor immune response. The technology is designed to integrate with standard-of-care treatments and can be adapted for infectious disease applications as well.
Target Audience
Primary customers are oncology pharmaceutical companies and clinical research organizations developing therapies for low‑immunogenic solid tumors and hematologic malignancies.
Features
- Proprietary biomaterial scaffold that creates a physical niche for immune cell recruitment and activation
- Modular loading capability for a range of immunomodulatory agents (cytokines, CpG, mRNA, etc.)
- 3D spatiotemporal control of bioactive component release to enhance response magnitude and durability
- Ability to reprogram immune cells in situ, overcoming tumor-induced tolerance
- Compatibility with existing oncology treatment regimens and potential extension to infectious disease therapies